prikaz prve stranice dokumenta Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.
Access restricted to all Croatian higher education institution's students and staff
Scientific paper - Original scientific paper
Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.
Surgical endoscopy, 31 (2017); 602-610. https://doi.org/10.1007/s00464-016-5004-9
Hauser, Goran; Blažević, Ivana; Salkić, Nermin; Poropat, Goran; Giljača, Vanja; Bulić, Zlatko; Štimac, Davor

Cite this document

Hauser, G., Blažević, I., Salkić, N., Poropat, G., Giljača, V., Bulić, Z. & Štimac, D. (2017). Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.. Surgical endoscopy, 31., 602-610. doi: 10.1007/s00464-016-5004-9

Hauser, Goran, et al. "Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.." Surgical endoscopy, vol. 31, 2017, pp. 602-610. https://doi.org/10.1007/s00464-016-5004-9

Hauser, Goran, Ivana Blažević, Nermin Salkić, Goran Poropat, Vanja Giljača, Zlatko Bulić and Davor Štimac. "Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.." Surgical endoscopy 31 (2017): 602-610. https://doi.org/10.1007/s00464-016-5004-9

Hauser, G., et al. (2017) 'Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.', Surgical endoscopy, 31, pp. 602-610. doi: 10.1007/s00464-016-5004-9

Hauser G, Blažević I, Salkić N, Poropat G, Giljača V, Bulić Z, and sur.. Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.. Surgical endoscopy [Internet]. 2017 [cited 2024 December 26];31:602-610. doi: 10.1007/s00464-016-5004-9

G. Hauser, et al., "Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.", Surgical endoscopy, vol. 31, pp. 602-610, 2017. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:430409. [Accessed: 26 December 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.
AuthorGoran Hauser
AuthorIvana Blažević
AuthorNermin Salkić
AuthorGoran Poropat
AuthorVanja Giljača
AuthorZlatko Bulić
AuthorDavor Štimac
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Background and Aims: We aimed to compare the efficacy of prophylactic, parenterally administered ceftazidime and rectally applied diclofenac sodium for the prophylaxis of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). Methods: We prospectively enrolled patients who underwent ERCP. In a doubleblinded randomized controlled trial, patients received a suppository containing diclofenac sodium rectally (100 mg) and placebo intravenously (group A) or ceftazidime intravenously (1 g) and placebo rectally (group B) immediately before the procedure. The serum and urine amylase levels were recorded and the patients were clinically evaluated after ERCP. Results: Of the 272 patients enrolled (group A: 129 ; group B: 143), 32 developed pancreatitis (group A: 11 [8.5%] ; group B: 21 [14.7%] ; P = 0.17 ; relative risk = 1.72 ; 95% confidence interval [CI] = 0.86-3.43). The severity of the pancreatitis or complications did not significantly differ between the groups. A serum amylase level of ≥ 560 U/L and urine amylase level of ≥ 1150 U/L indicated a positive likelihood ratio for post-ERCP pancreatitis of ≥ 10. Moreover, the threshold visual analog scale score of ≤ 5 for abdominal pain after ERCP had excellent diagnostic potential for predicting the presence or absence of post-ERCP pancreatitis. Conclusions: The PEP incidence did not differ between the ceftazidime and diclofenac sodium groups. In patients with nonsteroidal anti-inflammatory drug contraindications, antibiotics can be considered a safe alternative to diclofenac sodium for PEP prevention. Moreover, the visual analog scale for abdominal pain has excellent diagnostic value for predicting PEP. Clinical trials.gov number, NCT 01784445.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleSurgical endoscopy
Numberingvol. 31, pp. 602-610
p-ISSN0930-2794
DOIhttps://doi.org/10.1007/s00464-016-5004-9
URN:NBNurn:nbn:hr:184:430409
Publication2017
ProjectNumber: 13.06.1.2.30
Title (croatian): Antimikrobna profilaksa u liječenju bolesnika s akutnim pankreatitisom
Leader: Davor Štimac
Jurisdiction: Croatia
Funding stream: Sveučilište u Rijeci
Document URLhttp://bib.irb.hr/913175
Type of resourceText
Access conditionsRestricted access
Terms of useLicence In copyright icon
Created on2022-02-16 16:46:35